US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

38.02 -0.91 (-2.34%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Xenon Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Ratings for Xenon Pharmaceuticals ↗
 
Via Benzinga
News headline image
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Where Xenon Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Xenon Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value ↗
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗
 
Via Benzinga
News headline image
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI ↗
General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings and sales and raised guidance. The company said global deliveries of its automobiles 
Via Benzinga
News headline image
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
News headline image
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company ↗
A recent merger between Applied UV Inc. (NASDAQ: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment... 
Via Benzinga
News headline image
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >